A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration

BACKGROUND: There is a dearth of patient, preference-based cost-effectiveness analyses evaluating genetic testing for neovascular age-related macular degeneration (NVAMD). METHODS: A Value-Based Medicine, 12-year, combined-eye model, cost-utility analysis evaluated genetic testing of Category 3 AMD...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Int J Retina Vitreous
Prif Awduron: Brown, Gary C., Brown, Melissa M., Lieske, Heidi B., Lieske, Philip A., Brown, Kathryn S.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2015
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5088478/
https://ncbi.nlm.nih.gov/pubmed/27847612
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40942-015-0016-5
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg